Breaking News India,Latest Franchise News India,Lupin Pharma plans to grow its franchise business in India,Pharma major Lupin Limited (Lupin) has launched Cialis (tadalafil), an oral PDE5 inhibitor, for the treatment of erectile dysfunction (ED) in adult males. Cialis was shown to improve erectile function compared to placebo up to 36 hours following dosing. Cialis tablet is available in 10 mg and 20 mg strengths. The product is currently marketed in over 100 countries.

Lupin has acquired the rights to market, promote and distribute Lilly’s Erectile Dysfunction (ED) product, Cialis through its specialty field force while Lilly will be responsible for manufacturing and importing the product. Lupin is already promoting and distributing Lilly’s Huminsulin range of products and rapid acting insulin analog under the brand names Lispro and Eglucent.

The PDE-5 market in India is valued at around INR 390 crore, out of which Tadalafil contributes around 23%. The market size has doubled since 2012 and is growing annually at 15%. As per a study#, 52% men between the age 40 to 70 years suffer from erectile dysfunction (ED) of various type ranging from mild to severe. ED causes depression, low self-esteem and affects the quality of life.

Commenting on the launch, Mr Rajeev Sibal, President – India Region Formulations, Lupin said, “We are very happy with the addition of Cialis to our business portfolio. It heralds Lupin’s entry into the fast growth PDE-5 inhibitors market which will address the unmet medical need in ED space in India. The launch demonstrates Lupin’s commitment to grow its brand franchise in India and bring meaningful products to patients in the country.”

“We are pleased to expand our relationship with Lupin, with whom we have successfully partnered in the past. Cialis is a new treatment option for men with ED. Today, Erectile dysfunction is a significant medical condition affecting large number of Indian men, this partnership will help expand our reach to more patients. Lilly is committed to bringing innovative products to India” said Edgard Olaizola, Managing Director, Eli Lilly and Company (India) Pvt. Ltd.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Eli Lilly and Company (India) Pvt. Ltd. (Lilly), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA. Since its inception in India in 1993, Eli Lilly and Company (India) Pvt. Ltd. has been committed to developing and marketing pharmaceutical products to treat diabetes, lung cancer and gastric cancer, osteoporosis and growth-hormone deficiency.



Related Post:

1. Nestle plans to bring global brands in India

2. Sachin Tendulkar launched branded smart phone on flipkart

3. ORRA plans to open 10 franchise stores this fiscal

4. Jewellery brand TBZ opening 4th franchise in Jamnagar Gujarat

5. UK based Sothebys plans to expands in South India